Galleri is a blood test that aims to detect over 50 types of cancer early. It analyzes cell-free DNA (cfDNA) and methylation patterns to identify potential cancer signals. The test is intended for ...
Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening. Objectives: ...
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings from the PATHFINDER study of ...
Nearly 70 percent of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening.1,2,3 The Cancerguard test can help address the unmet need by complementing existing ...
MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with ...
ClearNote Health Receives In Vitro Diagnostic Approval in United Kingdom for Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test ClearNote Health, a company focused on improving ...
MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback